For Investors

Unique opportunity to invest in the UK’s first vertically integrated medical cannabis company

Equinox aims to be a British medical cannabis champion, looking to supply British-grown medical cannabis products predominantly for British patients. As we build the UK’s first ‘Land-to-Brand’, vertically integrated medical cannabis company, we will focus on providing consistent, high-quality, EU-GMP approved cannabis for medical products. Our business model is to pursue wholesale distribution into the rapidly emerging UK medical cannabis market, estimated to reach over £7.5 billion by 2028.

Equinox was one of the first businesses to receive a controlled drug licence from the UK government to cultivate, extract, produce, store, import and export medical cannabis. We are also working to establish the UK as a research pioneer within the medical cannabis industry, developing proprietary formulations, intellectual property and driving innovation. With a first-mover advantage in the cultivation, extraction, production, sales and distribution of high THC UK medical cannabis, there are a number of attributes that differentiate us in our market. Equinox also intends to be a UK flag bearer overseas and supply international markets with high quality British medical cannabis. For more information, see our contact us.

Equinox has a number of clear differentiators from other players in the UK medical cannabis market:

Currently, the vast majority of the UK’s medical cannabis is imported, making it an expensive, complex and time-consuming process, reducing quality oversight and inhibiting market growth potential.

The UK medical cannabis market is poised for significant growth and has the potential to become one of the largest legal cannabis markets in the world, estimated to reach up to £7.5 billion by 2028. Medical cannabis legislation was introduced in 2018 after a series of political campaigns and initiatives. Ongoing political pressure, UK medical cannabis production and improving private patient access to cannabis, have the potential to result in the country becoming a leading multi-billion-pound market.

Home Office Licence

In an increasingly challenging licensing environment and high barriers to entry, we have a rare licence from the Home Office to grow and produce medicinal cannabis on our 20-acre UK site. This has given us a significant head start compared to other entrants, with approvals often taking up to three years to obtain.

Blue-Chip Board and Advisors

Backed by a strong institutional Board with a wealth of experience in medical cannabis, healthcare, finance and agriculture. Led by Mike Abbott as Non-executive Chairman, a British national who founded Columbia Care Inc. in 2012, growing it into one of the largest manufacturers of cannabis related pharmaceuticals in the US.

Experienced Management Team and Partners

Our experienced management team brings professionalism and industry acumen to the UK cannabis market, having operated across both cannabis and mainstream businesses for several decades. See more here.

Wholesale Business Model catering to UK medical cannabis businesses and high-quality demand from NHS and private sector

Our modular state of the art facility is planned to provide medical cannabis products which meet EU-GMP standards, cater to a variety of different needs within the industry and address the significant demand anticipated in the UK as the market matures, on a wholesale basis.

British Cannabis focused on British patients – insulated from Brexit and positioned for international expansion

Given the costs, time, and regulatory burdens associated with importing medical cannabis and post-Brexit uncertainties around European trade, we are well positioned to become a key supplier of medical cannabis to the UK market. The UK’s position on medical cannabis also makes Equinox a potential partner of choice for large overseas cannabis companies looking to enter the UK and EU market.

British Champion Brand and Market Leading R&D Activities

Equinox is an early mover in the development of proprietary cannabis IP in the UK through our focus on R&D. Equinox has already developed proprietary formulations and are also looking at creating entirely proprietary products. To fulfil our Land-to-Brand vision, we will ultimately introduce OXON, positioned as the Oxford medical cannabis brand, delivering high quality products that the medical community can prescribe with confidence.

Ability To Execute on M&A To Vertically Integrate and Improve Margin

Equinox and its leadership are well known in the UK and international cannabis market, with access to deal flow that has the potential to materially benefit the business.

Building a UK Market Leader, Partner of Choice and Exit Opportunities

UK first mover advantage with high barriers to entry will help to establish Equinox as a UK market leader, with prospective North American and European partnership opportunities, and scope for M&A. The purchase of UK-based cannabinoid therapeutic firm GW Pharmaceuticals for $7.2 billion by Jazz Pharmaceuticals is an example of potential for acquisition by a strategic buyer and demonstrates the growing legitimacy of cannabis-based drugs within the pharma industry.

ESG

Equinox is dedicated to improving the quality of life for all.

We are committed to conducting our business in a responsible, transparent and respectful way whilst limiting our impact on the natural environment, creating a safe and inclusive workplace and working with local communities. As such, the Board has adopted the ESG Policy below. This applies to Equinox, the directors and all employees, as well as contractors and service providers who perform activities for, or on our behalf.

Equinox is built on a solid foundation with the capabilities, knowledge, resources and expertise to deliver. We are committed to basing our cultivation and processes on science, nature and medical knowledge and research, gained over decades, in the single-minded pursuit of trusted, safe product.

Creating certified, licensed and standardised product requires attention to every detail and a rigorously controlled process from land to brand. Equinox is 100% vertically integrated to carefully manage and monitor genetic purity and potency, to ensure that every product reaches the highest standards in the industry.

Equinox is committed to championing the development and security of the cannabis industry in the UK. To lead this effort, we employ the latest technology and innovations, to set a new path for cultivation, yield and processing that represents a paradigm of world-class production and supply.

Improvement is at the core of Equinox. We consistently challenge our methods and understanding in pursuit of higher quality, efficiency and conservation. Ultimately we seek to improve lives, through the development and supply of groundbreaking medicinal products for essential treatments that deliver quality-of-life.

Equinox and its Directors seek to carry on the Company’s business in a manner that:

  1. Complies with applicable laws and respects international good practice
  2. Provides safe and healthy working conditions for employees and contractors
  3. Establishes and maintains communication channels between employees and management to provide employees with the opportunity to present their views to management
  4. Promotes the fair treatment of all employees, irrespective of matters such as race, gender, nationality, disability, political or religious beliefs
  5. Recognises the importance of the sustainable use of natural resources and the protection of the environment;
  6. Considers the impact of any operations on local communities and seeks to ensure that potentially adverse health and safety, environmental and social effects are appropriately assessed, monitored and addressed
  7. Upholds high standards of business integrity and honesty and ensures that we do not directly or indirectly offer, pay, solicit or accept bribes in any form in either the public or private sector and to implement an anti-bribery and corruption compliance programme
  8. Implements social and environmental policies and procedures which enable identification, management and monitoring of any risks and provides a framework for action.

We believe in encouraging sustainability across all levels of our business. Our plans for our state of the art facility include holistic management of land, water and living resources to promote conservation and sustainable use to enhance human well-being. Our goal is to reduce the impact of harmful substances and hazardous waste on the environment and people.

We work with partners on several educational and charitable initiatives to tackle the residual negative consequences of cannabis policies. These include:

  • Medical cannabis education programs for Doctors and Patients.
  • Centre of Excellence and Innovation for Cannabis, including regional hubs for scientific assessments, technology transfer and advocacy.
  • Support for prison education programmes.

The Board is responsible for the overall management of Equinox, for setting its values, standards and policies, for approving its strategic aims and objectives, for approving its annual operating and capital expenditure budgets and for ensuring the maintenance of a sound system of internal controls and risk management (including financial, operational and compliance controls). The Board must also approve any changes to the capital, corporate and/or management structure of Equinox and any major contracts or transactions.

The Directors recognise the value and importance of high standards of corporate governance and intend, given the Company’s size and the constitution of the Board, to comply with the recommendations set out in the QCA Code. [Link to QCA Code: https://www.theqca.com/shop/guides/208266/corporate-governance-code-2018.thtml]